Crowdonomics
All companies
EPR-Technologies logo

EPR-Technologies

Operating

EPR-Technologies, Inc.

Healthcare · Technology · Gaithersburg, MD · Founded 2022

A cool way to save lives

Post-money valuation ⓘ
$65.1M
As of Dec 2022 · from Reg CF Offering (2022-09-03) · pre-money + amount raised, not a traded price
Total raised
$78,265
Across 2 rounds since 2022
Latest share price
$0.50
Reg CF · Preferred Stock · Sep 2022 offering price

Financials

FY2019–FY2026 (no data for FY2024) · from SEC filings · hover any figure for its source
$0
2019
$0
−$45
2020
$0
−$45
2021
$0
$86K
2022
$0
$8K
2023
2024no data
$0
2025
$0
2026
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019 reviewed*
FY2020 reviewed
FY2021 reviewed
FY2022 unaudited
FY2023 unaudited
FY2025 unaudited
FY2026 unaudited
Income statement
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
$0
Net income
$0
-$45
-$45
$85,598
$8,029
$0
$0
Taxes paid
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$39
$39
$24
$4,983
$179
$115
$115
Accounts receivable
$0
-$45
-$45
$81,615
$7,850
$0
$0
Total assets
$39
$39
$39
$4,983
$179
$115
$115
Short-term debt
$0
$0
$0
$0
$0
$0
$0
Long-term debt
$0
$0
$0
$0
$0
$0
$0
Total liabilities
$0
$0
$0
$0
$0
$0
$0
Other
Headcount
—
4
4
4
4
—
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$65.0M
pre-money
$65.1M
pre-money
Reg CF · Preferred · Mar 2022
Reg CF · Preferred · Sep 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$0.50$0.25$0.50
Mar 2022Sep 2022
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Principal holders% as the filing states it, Feb 28, 2022

  • Lyn Yaffe20,000,000 Preferred30.7%of company
  • Owned Common Lyn Yaffe20,000,000 shares30.7%of company
  • Xianren Wu20,000,000 Preferred30.7%of company

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $26.5K / $463.7KInvestors 36Post-money $65.1M
Raised $51.8K / $1.1MInvestors 104Post-money $65.1M

Team

6 people
Lyn Yaffe, M.D.
Co-Founder, Chairman, CEO, and Acting Secretary/Treasurer

Lyn Yaffe, M.D., EPR-Technologies, Inc., Co-Founder, Chairman, and CEO, was instrumental to the development of the concept of EPR during the research and development work at the Safar Center of Resuscitation Research, University of Pittsburgh, School of Medicine. Lyn has been dedicated to the concept and knowledgeable with regard to its emergency life-saving utility and potential applications in the field of resuscitation. Given the complexities of the EPR procedure and the demanding setting in which it will be used, these points take on special importance in this regard. Lyn and his team are therefore the best group to bring EPR forward successful development and product commercialization. Lyn completed undergraduate education at the Johns Hopkins University, School of Arts and Sciences, majoring in biophysics, in 1968. He received his M.D. degree at the University of Maryland, School of Medicine, in 1972, and completed pathology and research post-graduate training at Columbia University, New York, NY, with additional molecular biology research experience at the Roche Institute of Molecular Biology, in 1978. In the past decade, Lyn has been actively involved in research and development programs related to (1) patient/casualty monitoring strategies, (2) emergency hypothermia and rapid cooling techniques for point-of-injury care to induce ultra-profound cooling and suspended animation (EPR), and (3) semi-automated to automated, rapid vessel access techniques for therapeutic hypothermia, and a range of automated needle/catheter guidance and placement technologies.

Xianren Wu, M.D.
Co-Founder, Member of the Board of Directors, and Scientific Advisor

Xianren Wu, M.D., EPR-Technologies, Inc., Co-Founder and Board Member, Xianren Wu graduated from the Second Military Medical University in Shanghai in 1986, earned his Master of Medicine in 1989 after completion of a three-year, research-oriented program, and was trained in clinical anesthesiology. He was an anesthesiologist in Shanghai for 7 years. Since 1996, he was a full-time researcher in resuscitation medicine, working as a research fellow in Basel, Switzerland, for 3½ years and 6 years at the Safar Center for Resuscitation Research, University of Pittsburgh. His research focused on CPR, hemorrhagic shock and emergency preservation and resuscitation (EPR) technologies. Dr. Wu is currently a trauma anesthesiologist at the Geisinger Medical Center in Danville, PA. Dr. Wu’s role in EPR-Technologies, Inc. is a senior, co-founding, Scientific Advisor, in compliance with the rules and regulations of the Geisinger Medical Center. Mr. Wu's primary occupation is with the Geisinger Medical Center. He currently serves on an as-needed basis in his role with EPR-Technologies, Inc.

Lyn Yaffe
CEO, Secretary, Treasurer, Chairman, CFO/Principal Accounting Officer
Thomas Hardiman
Executive Vice President and Member of the Board of Directors

Thomas Hardiman serves as EPR Technologies’ Executive Vice President for Financing, Continuing Medical Education, and Training, while also currently handling EPR Technologies’ recruiting and sales plans. Tom’s experience includes 20-plus years commercial and government strategic marketing expertise in the medical device, pharmaceutical recall/returns, and medical personnel recruitment. Previously, as Vice President of Cine-Med, an AMA-accredited Education, Medical Communications, Marketing and Surgical Cinematography firm, Tom sourced, serviced, and supported unprecedented accredited and non-accredited commercial-Federal contracts. Tom currently works with industry contacts within the American Trauma Society, the American College of Surgeons, the Royal College of Surgeons, the Association of Operating Room Nurses, the United States Department of Defense, the Coalition Provisional Authority, the Iraqi Ministry of Health, the Department of Health and Human Services, and all branded and generic pharmaceutical manufacturers. Tom is an independent contractor with the City of Stamford and spends 20 hours/week working with EPR-Technologies. Utilizing his experience as a four-year Letterman and starting quarterback for Western Connecticut State University (WCSU), Tom has coached football, baseball and basketball for Fairfield, Connecticut Youth Sports and Wakeman Boys and Girls club for 10 years. He has also served as a Board Member for the WCSU Alumni Association as well as the Nationally Ranked Fairfield American Little League Baseball and Pop Warner Youth football programs. In his free time, Tom enjoys fishing, golfing, traveling, and spending time with his friends and family.

Brad Stezoski
Member of the Board of Directors

Brad Stezoski is a Board Member of EPR-Technologies. Brad received a Bachelor of Arts, Studio Arts, Degree from the University of Pittsburgh. He has experience in media, photography, and website design for the University of Pittsburgh Medical Center (UPMC), Department of Anesthesiology. Currently, Brad is with UPMC IT as an analyst, developer and support expert for administrative business web technologies for medical, community practice, education, and research-based Intranet sites, and is the Lead Developer of SharePoint sites for all administrative medical departments at UPMC. Mr. Stezoski's primary occupation is with UPMC Presbyterian Shadyside. He is the son of one of the original co-founders, William Stezoski, and represents the Stezoski Family on the Board of Directors. He currently serves 1-2 hours per week in his role with EPR-Technologies, Inc.

Xianren Wu
Scientific Advisor, Director

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 4 of 5 annual reports (FY2021–FY2025)

104 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARApr 27, 20260001912672-26-000001
    EDGAR
  • Form C-ARApr 1, 20240001665160-24-000293
    EDGAR
  • Form C-ARApr 3, 20230001665160-23-000529
    EDGAR
  • Form C-UJan 3, 20230001665160-23-000002
    EDGAR
  • Form C/ANov 28, 20220001665160-22-002978
    EDGAR
  • Form CAug 31, 20220001665160-22-002329
    EDGAR
  • Form C-UJun 30, 20220001665160-22-001944
    EDGAR
  • Form C/AMay 17, 20220001665160-22-001666
    EDGAR
Source: ManualCIK 0001912672AZShare price $0.50

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.